Autolus Therapeutics (Autolus Therapeutics) EV-to-Revenue : 516.55 (As of Apr. 29, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Autolus Therapeutics's enterprise value is $877.11 Mil. Autolus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.70 Mil. Therefore, Autolus Therapeutics's EV-to-Revenue for today is 516.55.

The historical rank and industry rank for Autolus Therapeutics's EV-to-Revenue or its related term are showing as below:

AUTL' s EV-to-Revenue Range Over the Past 10 Years
Min: -42.36 Med: 113.73 Max: 1103.09
Current: 516.55

During the past 8 years, the highest EV-to-Revenue of Autolus Therapeutics was 1103.09. The lowest was -42.36. And the median was 113.73.

AUTL's EV-to-Revenue is ranked worse than
92.75% of 1034 companies
in the Biotechnology industry
Industry Median: 7.69 vs AUTL: 516.55

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-29), Autolus Therapeutics's stock price is $3.80. Autolus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Therefore, Autolus Therapeutics's PS Ratio for today is 422.22.

Autolus Therapeutics EV-to-Revenue Historical Data

The historical data trend for Autolus Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics EV-to-Revenue Chart

Autolus Therapeutics Annual Data

Trend

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

140.77

1,524.12

121.08

-4.74

550.42

Autolus Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-4.74	0.37	20.95	36.45	550.42

Competitive Comparison of Autolus Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Autolus Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Autolus Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's EV-to-Revenue falls into.

Autolus Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Autolus Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	877.106	/	1.698
	=	516.55

Autolus Therapeutics's current Enterprise Value is $877.11 Mil.
Autolus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.70 Mil.

Autolus Therapeutics (NAS:AUTL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Autolus Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	3.80	/	0.009
	=	422.22

Autolus Therapeutics's share price for today is $3.80.
Autolus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

Autolus Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Autolus Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Autolus Therapeutics (Autolus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

6A3A:Germany

Address

191 Wood Lane, The MediaWorks, London, GBR, W12 7FP

Website

https://www.autolus.com

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.